In-Silico docking of HIV-1 integrase inhibitors reveals a novel drug type acting on an enzyme/DNA reaction intermediate.
about
Broad antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor elvitegravir (JTK-303/GS-9137)Structure-analysis of the HIV-1 integrase Y143C/R raltegravir resistance mutation in association with the secondary mutation T97A"Shock and kill" effects of class I-selective histone deacetylase inhibitors in combination with the glutathione synthesis inhibitor buthionine sulfoximine in cell line models for HIV-1 quiescence.Response of a simian immunodeficiency virus (SIVmac251) to raltegravir: a basis for a new treatment for simian AIDS and an animal model for studying lentiviral persistence during antiretroviral therapy.A dynamic model of HIV integrase inhibition and drug resistance.Anti-HIV drug development through computational methods.Structure-based modeling of the functional HIV-1 intasome and its inhibitionPolymorphisms of HIV-2 integrase and selection of resistance to raltegravirTargeting the transposase domain of the DNA repair component Metnase to enhance chemotherapyMolecular dynamics approaches estimate the binding energy of HIV-1 integrase inhibitors and correlate with in vitro activity.Computer tools in the discovery of HIV-1 integrase inhibitorsDesign, Synthesis, and Biological Evaluation of 1,2-Dihydroisoquinolines as HIV-1 Integrase Inhibitors.Human immunodeficiency virus integrase inhibitors efficiently suppress feline immunodeficiency virus replication in vitro and provide a rationale to redesign antiretroviral treatment for feline AIDSHIV-1 drug resistance mutations: an updated framework for the second decade of HAARTResistance mutations in human immunodeficiency virus type 1 integrase selected with elvitegravir confer reduced susceptibility to a wide range of integrase inhibitorsPiecing together the structure of retroviral integrase, an important target in AIDS therapyHuman cellular restriction factors that target HIV-1 replication.Comparative biochemical analysis of HIV-1 subtype B and C integrase enzymes.Targets for inhibition of HIV replication: entry, enzyme action, release and maturation.Molecular dynamics of HIV1-integrase in complex with 93del - a structural perspective on the mechanism of inhibition.Nuclear landscape of HIV-1 infection and integration.Examining structural analogs of elvitegravir as potential inhibitors of HIV-1 integrase.Characterization of the HIV-1 integrase chromatin- and LEDGF/p75-binding abilities by mutagenic analysis within the catalytic core domain of integrase.Effect of Silver Nanoparticles Against the Formation of Biofilm by Pseudomonas aeruginosa an In silico Approach.Emerging role of integrase inhibitors in the management of treatment-experienced patients with HIV infection.Natural variation of HIV-1 group M integrase: implications for a new class of antiretroviral inhibitors.Analysis of natural sequence variation and covariation in human immunodeficiency virus type 1 integrase.The Retrovirology Open Access experience.Please comment, but with civility.HIV-1 IN alternative molecular recognition of DNA induced by raltegravir resistance mutations.Selective and rapid determination of raltegravir in human plasma by liquid chromatography-tandem mass spectrometry in the negative ionization mode.Identification of novel HIV-1 integrase inhibitors using shape-based screening, QSAR, and docking approach.Pharmacophore development and docking studies of the hiv-1 integrase inhibitors derived from N-methylpyrimidones, Dihydroxypyrimidines, and bicyclic pyrimidinones.
P2860
Q24656978-6452BFE9-ECC4-4083-8A9B-FA035691B32FQ28478722-D1E45B8D-5389-44A4-84A7-515D60AF4D93Q30488246-A0145469-63E7-440D-AC40-03F48E2D25EEQ30494064-65F1A5B5-C1AF-49DA-AF51-02286CF0B418Q33758191-94EDABA1-10BB-426B-B8CD-51B91D43C3BFQ33803979-322C5926-A497-440C-942C-5A32A4DC5B31Q34115746-FEF6F278-FA98-445F-87AB-E5D61193568CQ34426605-EA08233D-D98F-48D7-8716-E43E9F363926Q34454737-D8F4085D-1581-4E80-931C-1364C86FBE38Q35666439-CA647F9D-A2A5-41F4-BC9F-8E3B4E698D34Q36145611-3ADE2DD7-BAFA-4C97-9B1B-195829101B5BQ36146699-4017D769-D2E7-4015-95D7-BC95032A5075Q36462709-90DFB373-1E68-49C8-9FEF-A2A53B837DB4Q36900010-7C05AD0A-15EE-4A16-B085-F44DB499122BQ36949688-F3224DFE-7553-4B7C-910D-35F3C651A526Q37353786-61193C53-1BC1-438D-8D72-964544AC9322Q37382519-3967F335-072A-4A3C-8E5F-5C779B5D9176Q37426900-6C42637E-A79C-4B1F-BA26-601BB65869B5Q37979697-4C8E60EF-52A4-4211-A386-368F98E7C90DQ38328136-3791730A-8B42-4304-9BFB-142F1AD227C4Q39035944-599B7D48-A877-4E72-B5AA-E4D840F760DBQ39228260-4800A2DC-5E3D-4B5C-AEAF-3C8D43666E93Q39724164-B25C8425-FCEE-46BC-9829-6D04D42110A6Q39746282-0FF6D05D-6E1E-45EE-A061-301FBC08EC0FQ41434760-AFDA1283-5DF7-49A8-8CE6-A2BE3BBB9751Q42746719-E9333B13-A22F-46A3-AA9B-91FDBBD25B95Q42756221-7BCCE53B-59B9-4891-B6D1-03563109BDC5Q42945038-0FD8AE0D-B618-4327-9825-105D92155020Q43228570-39EADE6C-9D87-45F2-B573-C66157B82F77Q45923447-CAC3CFE4-253D-48F5-97EE-376ECB0C16B3Q49224464-7894C012-8125-4262-BD52-C73AC06D4978Q54537227-AA4AF2C6-8337-4274-AC9B-10254140347AQ54594545-1019DF0A-56E5-46DF-985D-B7EF00F6A88F
P2860
In-Silico docking of HIV-1 integrase inhibitors reveals a novel drug type acting on an enzyme/DNA reaction intermediate.
description
2007 nî lūn-bûn
@nan
2007 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի մարտին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
In-Silico docking of HIV-1 int ...... yme/DNA reaction intermediate.
@ast
In-Silico docking of HIV-1 int ...... yme/DNA reaction intermediate.
@en
type
label
In-Silico docking of HIV-1 int ...... yme/DNA reaction intermediate.
@ast
In-Silico docking of HIV-1 int ...... yme/DNA reaction intermediate.
@en
prefLabel
In-Silico docking of HIV-1 int ...... yme/DNA reaction intermediate.
@ast
In-Silico docking of HIV-1 int ...... yme/DNA reaction intermediate.
@en
P2860
P356
P1433
P1476
In-Silico docking of HIV-1 int ...... yme/DNA reaction intermediate.
@en
P2093
Andrea Savarino
P2860
P2888
P356
10.1186/1742-4690-4-21
P577
2007-03-20T00:00:00Z
P5875
P6179
1021091754